indalapril
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2002 (NCT00157586)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- AcetylcholinesteraseINHIBITOR
ACHE inhibitor
- Angiotensin-converting enzymeINHIBITOR
Angiotensin-converting enzyme inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1- Mol. weight
- 452.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL589583 ↗
Also known as
- alindapril
- cv 3317
- cv-3317
- cv-3317
- cv-3317
- cv-3317
- delapril
- delapril
- delapril
- delapril
- delapril
- delapril
- derapril
- indalapril
- n-(2,3-dihydro-1h-inden-2-yl)-n-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)alanyl)glycine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00627952 | Phase 3 | Nov 1, 2007 | Chiesi, University of Erlangen-Nuremberg |
| NCT00157586 | Phase 3 | Feb 1, 2002 | Mario Negri Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 1 | 0 | 1 | 2007 |
| Mario Negri Institute | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1